Abbott Cephea Mitral Valve Disease Registry (NCT07069673)
🩺 Plain-English Summary (8th-Grade Level)
The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of correcting symptomatic mitral valve disease on clinical outcomes in patients that could be candidates for Transcatheter Mitral Valve Replacement and may also inform future regulatory or reimbursement submission strategies for the Cephea Mitral Valve System.
Who can join: Review the eligibility criteria below.
Location: University Hospital - Univ. of Alabama at Birmingham (UAB) — Birmingham, Alabama
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- University Hospital - Univ. of Alabama at Birmingham (UAB) — Birmingham, Alabama
- Phoenix Cardiovascular Research Group — Phoenix, Arizona
- Los Robles Regional Medical Center — Thousand Oaks, California
- Piedmont Heart Institute — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Northwestern Memorial Hospital — Chicago, Illinois
- Ascension St. Vincent — Indianapolis, Indiana
- Via Christi Regional Medical Center - St. Francis Campus — Wichita, Kansas
- Minneapolis Heart Institute — Minneapolis, Minnesota
- Providence St. Patrick Hospital — Missoula, Montana
- St. Francis Hospital — Roslyn, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
- Atrium Health - Carolinas Medical Center — Charlotte, North Carolina
- The Cleveland Clinic Foundation — Cleveland, Ohio
- Allegheny General Hospital - ASRI — Pittsburgh, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- TriStar Centennial Medical Center — Nashville, Tennessee
- Ascension Saint Thomas — Nashville, Tennessee
- Vanderbilt Heart & Vascular Institute — Nashville, Tennessee
- Houston Methodist — Houston, Texas
- UTHealth Memorial Hermann — Houston, Texas
- Intermountain Medical Center — Murray, Utah
- Sentara Norfolk General Hospital — Norfolk, Virginia
📞 Contact the Study Coordinator
Phone: (612) 816-4605
Email: cepheamvdregistry@abbott.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mitral Regurgitation
- Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation — Birmingham, Alabama
- SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation — Los Angeles, California
- Beating Heart Mitral Valve Repair With the HARPOON™ System — San Francisco, California
- Prospective Treatment Algorithm Guiding Repair of Severe Ischemic Mitral Regurgitation — Ottawa, Ontario
- LEFT ATRIAL MONITORING IN PATIENTS BEFORE AND AFTER MITRAL SURGERY - LAMBDA STUDY — Ottawa, Ontario
- CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry — Tucson, Arizona
Explore by condition: All Mitral Regurgitation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.